Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 1/20 | 0.53 |
| ▸ | PDE2A | O00408 | 1/20 | 0.40 |
| ▸ | RIPK1 | Q13546 | 7/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.39 |
| ▸ | GLS | O94925 | 1/20 | 0.39 |
| ▸ | CETP | P11597 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | MPO | P05164 | 1/20 | 0.38 |
| ▸ | GPR3 | P46089 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22957678 | 0.84 | ADRB2 (0.49) | ADRB2GLS | |
| SCHEMBL22957787 | 0.82 | APLNR (0.50) | ADRB2LMNAMEN1MAPTKMT2A | |
| SCHEMBL14959716 | 0.82 | ADRB2 (0.44) | ADRB2PDE2ALMNAFFAR4MPO | |
| SCHEMBL30483677 | 0.82 | ADRB2 (0.54) | ADRB2FFAR4GLSCETPMEN1 | |
| SCHEMBL15599254 | 0.82 | PDE2A (0.44) | ADRB2PDE2AFFAR4MPOGPR3 | |
| SCHEMBL22624065 | 0.81 | ADRB2 (0.47) | ADRB2RIPK1FFAR4GLSMEN1 | |
| SCHEMBL24018765 | 0.81 | ADRB2 (0.46) | ADRB2FFAR4GLSMEN1MAPT | |
| SCHEMBL22957676 | 0.80 | ADRB2 (0.46) | ADRB2PDE2ARIPK1FFAR4GLS | |
| SCHEMBL22957859 | 0.80 | ADRB2 (0.44) | ADRB2PDE2ARIPK1FFAR4GLS | |
| SCHEMBL23761199 | 0.79 | GLS (0.48) | ADRB2RIPK1GLS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3743430-B1 | AMINOPYRROLOTRIAZINES AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2023-08-02 | — | — | EP | disclosed |
| US-10913738-B2 | Aminotriazolopyridines as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-02-09 | — | — | US | disclosed |
| WO-2019147782-A1 | AMINOPYRROLOTRIAZINES AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-08-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10913738-B2 | Aminotriazolopyridines as kinase inhibitors | RIPK1, RIPK3, RIPK4 | ADRB2 3001/4885PDE2A 1905/4885RIPK1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.